Latest / This Week In Medicine / 8 11 2025

Transcript

8 11 2025 · This Week In Medicine

• 0:00
  [SPEAKER_00]: Welcome to this week in medicine, your filtered medical journal summary.
• 0:03
  [SPEAKER_00]: Looking to stay up to date with the latest medical research but short on time?
• 0:07
  [SPEAKER_00]: This week in medicine has you covered.
• 0:09
  [SPEAKER_00]: Our AI-generated podcast provides you with a convenient, on the go solution to keep you informed about the most significant developments in the medicine field.
• 0:16
  [SPEAKER_00]: Each episode offers a filtered and concentrated summary of key journal articles, allowing you to stay informed without the need to sift through pages of research papers.
• 0:24
  [SPEAKER_00]: With this week in medicine, listening is faster than reading, and you can consume valuable medical knowledge while commuting, exercising, or during your daily routine.
• 0:32
  [SPEAKER_01]: Hi, this week in medicine, we will be discussing.
• 0:35
  [SPEAKER_01]: First we will be discussing articles in New England Journal of Medicine.
• 0:39
  [SPEAKER_01]: Phenharonon with Emperglyphlosin in chronic kidney disease and Type II diabetes.
• 0:44
  [SPEAKER_01]: Background Limited evidence exists to support the simultaneous initiation of sodium glucose, co-transporter, two inhibitors and Phenharonon, a non-steroidal mineralocorticoid receptor antagonist in persons with chronic kidney disease and Type II diabetes conclusions.
• 1:02
  [SPEAKER_01]: Among persons with both chronic kidney disease and type II diabetes, initial therapy with phenharonone plus amperglyph lozen led to a greater reduction in the urinary albumin to creatinine ratio than either treatment alone.
• 1:15
  [SPEAKER_01]: Next article.
• 1:17
  [SPEAKER_01]: Ciprofloxicin versus amino glycosides ciprofloxicin for bubonic plague.
• 1:22
  [SPEAKER_01]: Background.
• 1:23
  [SPEAKER_01]: Plague is a high-consequence infectious disease with epidemic potential.
• 1:27
  [SPEAKER_01]: Current treatment guidelines are based on weak evidence conclusions.
• 1:31
  [SPEAKER_01]: Oral Ciprofloxicin monotherapy for ten days was non-inferior to an amino-glicacide Ciprofloxicin sequential combination for the treatment of patients with bubonic plague.
• 1:42
  [SPEAKER_01]: Next article.
• 1:43
  [SPEAKER_01]: Vipto Guestrant, a protac estrogen receptor degrader, in advanced breast cancer.
• 1:48
  [SPEAKER_01]: Background.
• 1:50
  [SPEAKER_01]: Vipto Guestrant is an oral proteolysis targeting chimera, protac, estrogen receptor, ER, degrader that directly harnesses the ubiquitin proteosum system.
• 2:01
  [SPEAKER_01]: Among patients with ER-positive, her two-negative advanced breast cancer, Viptigastrant, was associated with significantly longer progression-free survival than full-vestrant in the subgroup with ESR-one mutations, but not in the full-patient population.
• 2:17
  [SPEAKER_01]: Next article.
• 2:18
  [SPEAKER_01]: First line commesistrant for emerging ESR-One mutated advanced breast cancer.
• 2:23
  [SPEAKER_01]: Background.
• 2:24
  [SPEAKER_01]: Mutations in ESR-One are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor, plus a cycline dependent kinase four and six, CDK-four slash six, inhibitor for advanced breast cancer.
• 2:38
  [SPEAKER_01]: Commesistrant, a next-generation selective estrogener receptor, ER, degrader, and complete ER antagonist.
• 2:46
  [SPEAKER_01]: Has shown antitumer activity in ER positive advanced breast cancer to conclusions.
• 2:51
  [SPEAKER_01]: In patients with ER positive, her two negative advanced breast cancer with an ESR one mutation that emerged during treatment, those who were switched to commesis stront with continuation of a CDK four slash six inhibitor during first-line therapy, had significantly longer progression-free survival than those who maintained the aromatase inhibitor combination.
• 3:18
  [SPEAKER_01]: Next we will be discussing articles from Journal of American Medical Association.
• 3:23
  [SPEAKER_01]: All to plays for acute eschemic stroke at four point five to twenty four hours.
• 3:27
  [SPEAKER_01]: Question.
• 3:28
  [SPEAKER_01]: Does intravenous all to plays administered four point five to twenty four hours after acute eschemic stroke onset improve outcomes and patients with salvageable brain tissue and no initial plan for thrombectomy findings?
• 3:41
  [SPEAKER_01]: In this randomized clinical trial of three hundred seventy two patients, forty percent receiving all to please achieved functional independence at ninety days versus twenty six percent with standard care, a statistically significant difference, meaning in patients with salvageable brain tissue identified by profusion imaging who did not initially receive thrombectomy.
• 4:01
  [SPEAKER_01]: All to plays given four point five to twenty four hours after acute ischemic stroke onset may improve functional outcomes.
• 4:14
  [SPEAKER_01]: Next we will be discussing articles from Annals of Internal Medicine.
• 4:18
  [SPEAKER_01]: Efficacy of a very low calorie weight loss diet plus exercise compared with exercise alone on hip osteoarthritis pain, a randomized controlled trial.
• 4:28
  [SPEAKER_01]: Background.
• 4:30
  [SPEAKER_01]: Exercise is recommended to manage hip osteoarthritis, but weight loss recommendations are conflicting dot objective.
• 4:37
  [SPEAKER_01]: To evaluate the efficacy of a weight loss diet added to exercise on change in hip pain conclusion.
• 4:43
  [SPEAKER_01]: Adding a weight loss diet to exercise did not change hip pain but improved most secondary outcomes.
• 4:55
  [SPEAKER_01]: Next we will be discussing articles in the field of hematology.
• 4:59
  [SPEAKER_01]: Here are the articles from JAMA oncology.
• 5:02
  [SPEAKER_01]: Modeling population level impacts of cell-free DNA screening for colorectal cancer in Canada.
• 5:08
  [SPEAKER_01]: Question.
• 5:09
  [SPEAKER_01]: How could introduction of cell-free DNA?
• 5:11
  [SPEAKER_01]: CFDNA based colorectal cancer screening impact incidence, mortality, and costs of screening in Canada.
• 5:18
  [SPEAKER_01]: Findings in this study.
• 5:19
  [SPEAKER_01]: Modeling suggested that CFDDNA screening could reduce incidence and mortality of colorectal cancer.
• 5:25
  [SPEAKER_01]: CFDIA testing resulted in costs of CAG-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB-USB
• 5:31
  [SPEAKER_01]: U.S.
• 5:31
  [SPEAKER_01]: one hundred sixty four dollars and six cents per health-adjusted person you're gained and could have earned zero point zero two five deaths per c-a-d one hundred thousand dollars US sixty nine thousand eight hundred seventy four dollars additional dollars spent compared with fecal immunochemical testing meaning c-f-d-a-d testing could have a beneficial role to improve colorectal cancer screening outcomes in Canada
• 5:55
  [SPEAKER_01]: If it improves patient uptake of screening, but would have little impact if utilization remained the same as fecal immunochemical testing.
• 6:08
  [SPEAKER_01]: Here are the articles from Journal of Clinical Oncology.
• 6:11
  [SPEAKER_01]: Randomized Phase II study of concurrent versus sequential pembrolismab in combination with shimmer radiation in locally advanced head and neck cancer.
• 6:20
  [SPEAKER_01]: Purpose.
• 6:21
  [SPEAKER_01]: The optimal timing of pembrolismab with shimmer radiation, CRT, in locally advanced, LA, head and neck squamous cell, carcinoma, HNSCC, is unknown conclusion.
• 6:33
  [SPEAKER_01]: CRT with sequential Pembrollism app met criteria for further study.
• 6:38
  [SPEAKER_01]: Immunos oppressive changes in the TME differed between arms, reflecting the impact of one dose of Pembrollism app in the concurrent arm.
• 6:52
  [SPEAKER_01]: Here are the articles from Journal of Hepatology of Phase I.B.
• 6:56
  [SPEAKER_01]: Randomized controlled trial of the far-one slash far-four agonist ICO subutate in MASH safety and efficacy of ICO subutate evaluated in MASH patients with F-one F-three stage fibrosis.
• 7:09
  [SPEAKER_01]: While the primary endpoint, MASH resolution without worsening of fibrosis was not met.
• 7:15
  [SPEAKER_01]: Improvements in fibrosis were observed.
• 7:17
  [SPEAKER_01]: Improvements in fibrosis were also observed using two pre-specified AI-assisted digital pathology approaches.
• 7:24
  [SPEAKER_01]: Prenounced decreases in markers of liver injury and inflammation in ICO subutate treated patients.
• 7:30
  [SPEAKER_01]: ICO subutate was generally safe and well tolerated.
• 7:40
  [SPEAKER_01]: Next we will be discussing articles in the field of gastroenterology.
• 7:44
  [SPEAKER_01]: Here are the articles from gastroenterology.
• 7:47
  [SPEAKER_01]: Risk of gastric adenocarcinoma after eradication of helicobacter pylori.
• 7:52
  [SPEAKER_01]: Background and aims.
• 7:54
  [SPEAKER_01]: Helicobacter pylori infection of the stomach is the main risk factor for gastric noncardia adenocarcinoma.
• 8:01
  [SPEAKER_01]: However,
• 8:02
  [SPEAKER_01]: Less is known on how eradication of H. Pilari influences the risk of this tumor over time, particularly in Western populations.
• 8:10
  [SPEAKER_01]: The aim of this study was to delineate how the risk of gastric noncardia adenocarcinoma develops over time after H. Pilari eradication treatment in a Western population.
• 8:21
  [SPEAKER_01]: Compared with the background population conclusion.
• 8:24
  [SPEAKER_01]: This study revealed a decreasing incidence of gastric non-cardia adenocarcinoma after age-pilori eradication treatment in five western populations.
• 8:33
  [SPEAKER_01]: The risk became virtually similar to the background population from eleven years after treatment.
• 8:45
  [SPEAKER_01]: Here are the articles from clinical gastroenterology.
• 8:48
  [SPEAKER_01]: lymphocytic esophagitis, a histologic pattern of various underlying disorders.
• 8:54
  [SPEAKER_01]: Background.
• 8:55
  [SPEAKER_01]: lymphocytic esophagitis, lie, is a rare condition that has been reported in several case studies, but its diagnostic criteria and clinical significance are inconsistent.
• 9:06
  [SPEAKER_01]: There are no established clinical associations, except for Crohn's disease and children.
• 9:10
  [SPEAKER_01]: Our study aimed to determine if patients with Ly have distinct demographic or clinical characteristics, when compared with patients with increased intrepidthelial lymphocytes, IEL, in their esophodial biopsy conclusion.
• 9:24
  [SPEAKER_01]: Our findings suggest that lymphocytic esophagitis is not a well-defined clinical pathologic entity.
• 9:30
  [SPEAKER_01]: But rather a rare and non-specific histologic pattern associated with various esophageal disorders.
• 9:37
  [SPEAKER_01]: Further studies should aim to differentiate between the underlying causes of this histologic pattern, rather than defining it as a single clinical pathologic entity.
• 9:52
  [SPEAKER_01]: Next we will be discussing articles in the field of infectious diseases.
• 9:56
  [SPEAKER_01]: Here are the articles from clinical infectious diseases.
• 9:59
  [SPEAKER_01]: Target trial emulation of SARS-CoV-two infection versus no infection and risk of post-COVID-nineteen conditions in the Omicron variant versus prior errors.
• 10:09
  [SPEAKER_01]: Background.
• 10:10
  [SPEAKER_01]: coronavirus disease, COVID-nineteen, has been linked to the development of post-COVID-nineteen conditions, PCCs.
• 10:19
  [SPEAKER_01]: We investigated whether severe acute respiratory syndrome coronavirus too, SARS-CoV-II, infection increases the risk of selected PCCs or death, up to one year after infection, separately in the wild type, weight, alpha-transition, delta, and omicron errors, and by vaccination status conclusions.
• 10:38
  [SPEAKER_01]: Excess burden of PCCs and mortality persisted thirty-one to one hundred eighty days after infection in the Amacron era.
• 10:45
  [SPEAKER_01]: I'll be at a lower level than in the weight and delta iris.
• 10:49
  [SPEAKER_01]: Excess burden of mortality and most PCCs was much lower one hundred eighty-one to three hundred sixty-five days after infection and was observed in the Amacron era only among unvaccinated persons, suggesting a protective effect of vaccination.
• 11:10
  [SPEAKER_01]: Next we will be discussing articles in the field of rheumatology.
• 11:14
  [SPEAKER_01]: Peripheral biomarker signatures in rheumatoid arthritis associated interstitial lung disease.
• 11:20
  [SPEAKER_01]: Objective.
• 11:21
  [SPEAKER_01]: rheumatoid arthritis associated interstitial lung disease, RAILD, is a significant cause of morbidity and mortality among patients with RA.
• 11:31
  [SPEAKER_01]: Yet effective risk stratification for RAILD is lacking.
• 11:35
  [SPEAKER_01]: We sought to characterize unique peripheral blood biomarker signatures in RA that could improve RA-ILD discrimination beyond clinical and genetic risk factors.
• 11:45
  [SPEAKER_01]: Peripheral biomarker signatures are associated with RA-ILD and improve RA-ILD identification beyond clinical risk factors.
• 11:54
  [SPEAKER_01]: In addition to demonstrating the potential for peripheral biomarkers to aid RA-ILD risk stratification, these findings suggest diverse pathways are involved in RA-ILD pathogenesis.
• 12:11
  [SPEAKER_01]: Next we will be discussing articles in the field of cardiology.
• 12:15
  [SPEAKER_01]: Here are the articles from Circulation.
• 12:17
  [SPEAKER_01]: Abelachimob versus Riveroxaban in patients with atrial fibrillation on anti-platelet therapy.
• 12:24
  [SPEAKER_01]: A pre-specified analysis of the Azalea Timi-Seventy-One trial.
• 12:28
  [SPEAKER_01]: Background
• 12:29
  [SPEAKER_01]: Combining anti-platelet therapy, APT, with conventional anti-coagulants increases the risk of bleeding.
• 12:36
  [SPEAKER_01]: In the Azalea Timmy-seventy-one trial, safety and tolerability of Abelachimab, Ma-eight-sixty-eight, versus Riveroxaban and patients with atrial fibrillation.
• 12:47
  [SPEAKER_01]: The novel factor eleven inhibitor abolashimab, significantly reduced the risk of bleeding compared with river oxaban in patients with atrial fibrillation.
• 12:56
  [SPEAKER_01]: Whether the safety of combination antithrombotic therapy differs in the context of factor eleven inhibition has not been well-characterized.
• 13:04
  [SPEAKER_01]: Inhibition of Factor Eleven with Abelachimab, consistently reduced bleeding compared with Riveroxaban, regardless of concomitant APT use, with greater absolute reductions in bleeding in those requiring concomitant APT.
• 13:18
  [SPEAKER_01]: These data suggests that Factor Eleven inhibition may be a safe anticoagulant option in patients with atrial fibrillation requiring concomitant APT.
• 13:33
  [SPEAKER_01]: Here are the articles from journals of the American College of Cardiology.
• 13:37
  [SPEAKER_01]: Using compression stockings to prevent recurrence of vasovagal syncopy, a randomized sham-controlled trial.
• 13:44
  [SPEAKER_01]: Background.
• 13:45
  [SPEAKER_01]: Vasovagal syncopy, VVS, is a common yet challenging condition with limited effective treatments.
• 13:51
  [SPEAKER_01]: Elastic compression stockings, ECS, have been proposed as a potential therapy, but their real-world effectiveness remains unclear conclusions.
• 14:01
  [SPEAKER_01]: Treating syncopy with thigh high lower limb compression using ECS did not reduce the cumulative incidence of VVS recurrence and did not change VVS free survival.
• 14:11
  [SPEAKER_01]: Additionally, ECS did not reduce the frequency of multiple VVS episodes.
• 14:16
  [SPEAKER_01]: The results do not support routine use of thigh length ECS.
• 14:20
  [SPEAKER_01]: Although it may be helpful for selected patients when added to standard care, because our studies specifically tested thigh high ECS.
• 14:28
  [SPEAKER_01]: Future studies should aim to assess the effectiveness of more extensive compression targeting pelvic and abdominal venus pooling.
• 14:41
  [SPEAKER_01]: from jam a cardiology.
• 14:43
  [SPEAKER_01]: Cumulative life's essential eight scores and cardiovascular disease risk.
• 14:47
  [SPEAKER_01]: Question, what is the association between cumulative cardiovascular health, CVH, through young adulthood and incident cardiovascular disease, CVD, in midlife findings?
• 14:59
  [SPEAKER_01]: This cohort study found that higher cumulative life's essential eight, LE eight, score from age eighteen to forty-five years, independent of LE eight score at age forty-five years, and a positive slope of improving LE eight score from age eighteen to forty-five years, or significantly associated with lower hazards for incident CVD after age forty-five years.
• 15:21
  [SPEAKER_01]: Meaning cumulative CVH as measured by LE-eight.
• 15:24
  [SPEAKER_01]: Maybe a useful method for identifying the highest-risk young adults, and targeting them for primary and primordial prevention strategies.
• 15:38
  [SPEAKER_01]: Next we will be discussing articles in the field of endocrinology.
• 15:41
  [SPEAKER_01]: Here are the articles from Journal of Clinical Endocrinology and Metabolism.
• 15:46
  [SPEAKER_01]: Trends in osteoporosis drug therapy receipt among commercial and Medicare Advantage in Roles and the United States, twenty-eleven to twenty-twenty-two.
• 15:55
  [SPEAKER_01]: Context.
• 15:56
  [SPEAKER_01]: A national assessment of osteoporosis drug therapy, ODT,
• 16:01
  [SPEAKER_01]: Use can in form the extent of under diagnosis and under treatment of osteoporosis objective.
• 16:07
  [SPEAKER_01]: The aim was to describe trends in OTT use by age, sex, fragility fracture, and documented osteoporosis, conclusion.
• 16:16
  [SPEAKER_01]: OTT use for patients with documented osteoporosis has increased but remains low.
• 16:21
  [SPEAKER_01]: Low rates of OTT use for patients with fragility fractures and the absence of documented osteoporosis suggests that under diagnosis of osteoporosis contributes to under use of OTTs.
• 16:39
  [SPEAKER_01]: Here are the articles from diabetes care.
• 16:42
  [SPEAKER_01]: Lack of validity of the glucose management indicator in type one diabetes and pregnancy.
• 16:47
  [SPEAKER_01]: Objective.
• 16:49
  [SPEAKER_01]: The glucose management indicator, GMI, is widely used as a replacement for EPA-one C, but information in pregnancy is very limited.
• 16:58
  [SPEAKER_01]: We assessed the accuracy of GMI and associations with pregnancy outcomes in type one diabetes.cinclusions.
• 17:05
  [SPEAKER_01]: GMI is not an accurate replacement for Heaven One Sea in pregnancy and women with Type One Diabetes.
• 17:18
  [SPEAKER_01]: Next we will be discussing articles in the field of neurology.
• 17:21
  [SPEAKER_01]: Here are the articles from neurology.
• 17:24
  [SPEAKER_01]: Staten initiation and dementia incidents in a large healthcare system.
• 17:28
  [SPEAKER_01]: From nineteen ninety seven to twenty twenty a target trial emulation study.
• 17:33
  [SPEAKER_01]: Background and objectives.
• 17:35
  [SPEAKER_01]: Previous research of associations between statins and Alzheimer disease and Alzheimer disease related dementia's AD slash ADRDs has been limited by short follow up, small samples and confounding.
• 17:48
  [SPEAKER_01]: We aimed to estimate the association between the first statin prescription and incident AD slash ADRD among members of a large population based cohort of older adults discussion.
• 17:59
  [SPEAKER_01]: In this large emulated target trial, statin initiation was inconsistent with more than a three percent increase or decrease in the hazard of AD slash ADRD.
• 18:09
  [SPEAKER_01]: After the first year of follow-up, this intent to treat analysis does not directly quantify effects of long-term exposure to statins.
• 18:17
  [SPEAKER_01]: Associations in the first year likely reflect increased medical observation immediately after statin initiation.
• 18:30
  [SPEAKER_01]: Next we will be discussing articles in the field of pulmonary and critical care.
• 18:34
  [SPEAKER_01]: Here are the articles from the American Journal of Respiratory and Critical Care Medicine.
• 18:39
  [SPEAKER_01]: Endotypes of pseudomonas aruginoce infection in bronchiecticis are associated with inhaled antibiotic response.
• 18:46
  [SPEAKER_01]: Results from two randomized, double-blind, placebo-controlled face-three trials, ORbit-three, and ORbit-four rationale.
• 18:54
  [SPEAKER_01]: Replicate phase three trials of inhaled antibiotics and patients with bronchiectuses have produced inconsistent results, objectives.
• 19:02
  [SPEAKER_01]: This study investigated if different microbial and inflammatory endotypes are linked to antibiotic response in patients with chronic pseudomonas aruginocia infection.
• 19:12
  [SPEAKER_01]: Patients with chronic pyrrogenosa have heterogeneous microbiota and inflammatory profiles, influencing antibiotic treatment responses in bronchiectasis.
• 19:22
  [SPEAKER_01]: Future trials could be improved by patient stratification, including accounting for geographical differences and biomarkers to represent microbiota difference.
• 19:37
  [SPEAKER_01]: Next we will be discussing articles in the field of nephrology.
• 19:40
  [SPEAKER_01]: Here are the articles from Clinical Journal of American Society of Nephrology.
• 19:45
  [SPEAKER_01]: Sodium glucose co-transporter two inhibitor therapy and longitudinal changes in kidney function among veterans with autosomal dominant polycystic kidney disease.
• 19:55
  [SPEAKER_01]: Key points.
• 19:56
  [SPEAKER_01]: Sodium glucose co-transporter two inhibitor, SGLT-II, use, has not been extensively studied in autosomal dominant polycystic kidney disease, ATP-T-T.
• 20:08
  [SPEAKER_01]: In veterans with ADPC kidney function declined at a greater rate during the first three months post SGLT-II initiation, but subsequently attenuated.
• 20:18
  [SPEAKER_01]: In veterans with ADPD,
• 20:20
  [SPEAKER_01]: SGLT II vs. Dipotidal Pepto-Dase IV inhibitor use was associated with slower long-term kidney function decline.
• 20:33
  [SPEAKER_01]: Here are the articles from kidney international reports.
• 20:37
  [SPEAKER_01]: A systematic review of treatment for acute interstitial nephritis.
• 20:41
  [SPEAKER_01]: Introduction.
• 20:42
  [SPEAKER_01]: Acute interstitial nephritis, AIN, is a common cause of acute kidney injury.
• 20:47
  [SPEAKER_01]: It is characterized by tubular inflammation with eocinophils histologically.
• 20:52
  [SPEAKER_01]: The main state treatment for AIN includes early diagnosis, underlying infection or systemic disease treatment.
• 20:58
  [SPEAKER_01]: cessation of the offending agent and corticosteroid therapy when indicated.
• 21:03
  [SPEAKER_01]: This systematic review aims to evaluate the efficacy and safety of pharmacotherapy treatments for AIN by assessing treatment outcomes and adverse effects tons conclusion.
• 21:14
  [SPEAKER_01]: Consistent evidence supporting the use of corticosteroids for treating aim needs to be more comprehensive.
• 21:20
  [SPEAKER_01]: There needs to be a clear consensus on the optimal treatment regimen.
• 21:24
  [SPEAKER_01]: High-quality randomized controlled trials are required to help establish evidence-based guidelines for treating aim.
• 21:30
  [SPEAKER_00]: Thank you for listening to this week in medicine, your filtered medical journal summary.
• 21:35
  [SPEAKER_00]: Have a great week ahead, stay blessed and be humane.